ATE429914T1 - Verwendung von makroliden zur wiederherstellung der kornealempfindungen - Google Patents
Verwendung von makroliden zur wiederherstellung der kornealempfindungenInfo
- Publication number
- ATE429914T1 ATE429914T1 AT06787603T AT06787603T ATE429914T1 AT E429914 T1 ATE429914 T1 AT E429914T1 AT 06787603 T AT06787603 T AT 06787603T AT 06787603 T AT06787603 T AT 06787603T AT E429914 T1 ATE429914 T1 AT E429914T1
- Authority
- AT
- Austria
- Prior art keywords
- macrolids
- sensations
- restore corneal
- corneal
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2093—Leukaemia inhibitory factor [LIF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/183,355 US20070014760A1 (en) | 2005-07-18 | 2005-07-18 | Enhanced recovery following ocular surgery |
US11/263,737 US20070015697A1 (en) | 2005-07-18 | 2005-11-01 | Enhanced ocular neuroprotection and neurostimulation |
PCT/US2006/027713 WO2007011880A2 (en) | 2005-07-18 | 2006-07-18 | Enhanced ocular neuroprotection/neurostimulation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE429914T1 true ATE429914T1 (de) | 2009-05-15 |
Family
ID=37661858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06787603T ATE429914T1 (de) | 2005-07-18 | 2006-07-18 | Verwendung von makroliden zur wiederherstellung der kornealempfindungen |
Country Status (8)
Country | Link |
---|---|
US (4) | US20070014760A1 (de) |
EP (1) | EP2074994A1 (de) |
JP (1) | JP2009501797A (de) |
AT (1) | ATE429914T1 (de) |
BR (1) | BRPI0612859A2 (de) |
DE (1) | DE602006006575D1 (de) |
DK (1) | DK1904056T3 (de) |
ES (1) | ES2326550T3 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1882338A (zh) * | 2003-09-18 | 2006-12-20 | 马库赛特公司 | 经巩膜递送 |
US20060258698A1 (en) * | 2005-02-09 | 2006-11-16 | Sreenivasu Mudumba | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
WO2007019427A2 (en) * | 2005-08-08 | 2007-02-15 | Massachusetts Eye & Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US8492400B2 (en) | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
JP5506378B2 (ja) | 2006-03-23 | 2014-05-28 | 参天製薬株式会社 | 血管透過性に関連する疾患または病気のための製剤および方法 |
US20070237797A1 (en) * | 2006-03-28 | 2007-10-11 | Gholam A. Peyman | Neural Conduit Agent Dissemination |
US20070231360A1 (en) * | 2006-03-28 | 2007-10-04 | Minu, L.L.C. | Neural conduit agent dissemination |
US20070237722A1 (en) * | 2006-03-28 | 2007-10-11 | Peyman Gholam A | Neural conduit agent dissemination |
US20070297991A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Neural conduit agent dissemination for smoking cessation and other applications |
US8088789B2 (en) * | 2006-09-13 | 2012-01-03 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
EP2702993B1 (de) * | 2006-09-13 | 2017-12-06 | Elixir Medical Corporation | Makrocyclische lactonverbindungen und verfahren zu deren verwendung |
US10695327B2 (en) | 2006-09-13 | 2020-06-30 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
CN105380947A (zh) * | 2008-03-11 | 2016-03-09 | 万能医药公司 | 大环内酯化合物及它们的使用方法 |
EP2254412A4 (de) * | 2008-03-11 | 2012-05-09 | Elixir Medical Corp | Makrozyklische lactonverbindungen und verfahren für ihre verwendung |
EP2276420B1 (de) | 2008-04-04 | 2021-10-06 | Journey1, Inc. | Vorrichtung zur behandlung eines auges mit einem epithel mit einem defekt |
US20100158821A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
US8106111B2 (en) * | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
WO2011050365A1 (en) | 2009-10-23 | 2011-04-28 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
US8591025B1 (en) | 2012-09-11 | 2013-11-26 | Nexisvision, Inc. | Eye covering and refractive correction methods for LASIK and other applications |
EP2490635B1 (de) | 2009-10-23 | 2017-09-06 | Nexisvision, Inc. | Hornhaut-denervation zur behandlung von augenschmerzen |
IT1396607B1 (it) * | 2009-11-16 | 2012-12-14 | Hmfra Hungary Ltd Liability Company | Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso. |
KR20130107321A (ko) | 2010-10-25 | 2013-10-01 | 넥시스비젼, 인코포레이티드 | 시력용 눈 보호막을 인식하기 위한 방법 및 장치 |
AU2012249773A1 (en) | 2011-04-28 | 2013-11-07 | Nexisvision, Inc. | Eye covering and refractive correction methods and apparatus having improved tear flow, comfort, and/or applicability |
WO2014210186A2 (en) | 2013-06-26 | 2014-12-31 | Nexisvision, Inc. | Contact lenses for refractive correction |
US8678584B2 (en) | 2012-04-20 | 2014-03-25 | Nexisvision, Inc. | Contact lenses for refractive correction |
US12044905B2 (en) | 2011-04-28 | 2024-07-23 | Journey1 Inc | Contact lenses for refractive correction |
ITRM20110233A1 (it) * | 2011-05-10 | 2012-11-11 | Univ Calabria | Azitromicina, suoi sali o solvati farmaceuticamente accettabili per l?uso come neuroprotettori. |
WO2013011511A1 (en) | 2011-07-18 | 2013-01-24 | Mor Research Applications Ltd. | A device for adjusting the intraocular pressure |
RU2494707C2 (ru) * | 2011-12-23 | 2013-10-10 | Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") | Способ лечения открытоугольной глаукомы |
JP6298810B2 (ja) | 2012-04-20 | 2018-03-20 | ネクシスビジョン リクイデーション トラスト | 屈折矯正のためのコンタクトレンズ |
US9465233B2 (en) | 2012-04-20 | 2016-10-11 | Nexisvision, Inc. | Bimodular contact lenses |
EP2877195B1 (de) * | 2012-07-27 | 2018-03-21 | Curonz Holdings Company Limited | Verfahren zur behandlung von sehnervenschäden, ophthalmischer ischämie oder ophthalmischen reperfusionsschäden |
US9341864B2 (en) | 2013-11-15 | 2016-05-17 | Nexisvision, Inc. | Contact lenses having a reinforcing scaffold |
WO2015116559A1 (en) | 2014-01-29 | 2015-08-06 | Nexisvision, Inc. | Multifocal bimodulus contact lenses |
US20210275020A1 (en) * | 2016-07-18 | 2021-09-09 | Baylor College Of Medicine | Non-contact air esthesiometer |
IT201700066486A1 (it) * | 2017-06-15 | 2018-12-15 | Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A | Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche |
AU2019419468A1 (en) * | 2019-01-04 | 2021-07-15 | The Regents Of The University Of California | Compositions and methods for promoting angiogenesis in the eye |
WO2020228477A1 (zh) * | 2019-05-16 | 2020-11-19 | 沈阳福洋医药科技有限公司 | 一种用于预防、缓解和/或治疗纤维化的药物、组合产品及其应用 |
WO2021186041A1 (en) * | 2020-03-19 | 2021-09-23 | Universität Rostock | Josamycin for use in prevention and treatment of fibrosis |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US634693A (en) * | 1899-02-23 | 1899-10-10 | Carnegie Steel Company Ltd | Clamp for poles or columns. |
FR900520A (fr) | 1943-12-13 | 1945-07-02 | Nouveau système de trusquin | |
US4180646A (en) * | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4131648A (en) * | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4079038A (en) * | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4304767A (en) * | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
DE3851152T2 (de) * | 1987-09-03 | 1995-01-26 | Univ Georgia | Cyclosporin-augenmittel. |
US4946931A (en) * | 1989-06-14 | 1990-08-07 | Pharmaceutical Delivery Systems, Inc. | Polymers containing carboxy-ortho ester and ortho ester linkages |
DK0406791T3 (da) * | 1989-07-05 | 1995-03-27 | Fujisawa Pharmaceutical Co | Vandigt flydende præparat til ekstern anvendelse |
US5294604A (en) * | 1989-12-20 | 1994-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating ocular diseases by periocular administration of cyclosporine A or G |
IL102414A (en) * | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
US5788687A (en) * | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
US5457182A (en) * | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
US6179817B1 (en) * | 1995-02-22 | 2001-01-30 | Boston Scientific Corporation | Hybrid coating for medical devices |
US6413536B1 (en) * | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5968543A (en) * | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
JP2000507997A (ja) * | 1996-02-09 | 2000-06-27 | サーフェス ソルーションズ ラボラトリーズ インコーポレイテッド | 水性の親水性被覆組成物及びそれから製造した物品 |
AU2250097A (en) * | 1996-02-13 | 1997-09-02 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist |
US6013763A (en) * | 1996-06-04 | 2000-01-11 | Genentech, Inc. | Peptide variants of protein A |
KR100514277B1 (ko) * | 1996-09-13 | 2005-09-13 | 유겐가이샤 사이센딴이가꾸겡꾸쇼 | 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법 |
US5952371A (en) * | 1996-10-16 | 1999-09-14 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
AUPO427196A0 (en) * | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US20030181692A1 (en) * | 1997-06-06 | 2003-09-25 | Jian Ni | 207 human secreted proteins |
JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
US6015815A (en) * | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
JP2002509555A (ja) * | 1998-04-06 | 2002-03-26 | 藤沢薬品工業株式会社 | 新規用途 |
US6218423B1 (en) * | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
US6864232B1 (en) * | 1998-12-24 | 2005-03-08 | Sucampo Ag | Agent for treating visual cell function disorder |
US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US7063857B1 (en) * | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
US6596296B1 (en) * | 1999-08-06 | 2003-07-22 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
ES2206363T3 (es) * | 2000-04-07 | 2004-05-16 | Laboratoire Medidom S.A. | Formulaciones oftalmicas a base de ciclosporina, de acido hialuronico y de polisorbato. |
US6613355B2 (en) * | 2000-05-11 | 2003-09-02 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
US6440942B1 (en) * | 2000-12-22 | 2002-08-27 | Enanta Pharmaceuticals, Inc. | 14-membered macrolides derived from leucomycins |
US6462026B1 (en) * | 2001-02-16 | 2002-10-08 | Enanta Pharmaceuticals, Inc. | Bicyclic leucomycins |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US6436906B1 (en) * | 2001-04-02 | 2002-08-20 | Enanta Pharmaceuticals, Inc. | 9-amino-14-membered macrolides derived from leucomycins |
US6524606B1 (en) * | 2001-11-16 | 2003-02-25 | Ap Pharma, Inc. | Bioerodible polyorthoesters containing amine groups |
US20040162315A1 (en) * | 2002-07-23 | 2004-08-19 | Hellberg Mark R. | Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma |
US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US10575605B2 (en) | 2010-03-09 | 2020-03-03 | F.D. Worldwide Merchandise Group, Inc. | Jewelry stones set with prongs and invisible settings |
US10328305B1 (en) | 2016-06-06 | 2019-06-25 | Joseph D Maresh | Exercise machine |
-
2005
- 2005-07-18 US US11/183,355 patent/US20070014760A1/en not_active Abandoned
- 2005-11-01 US US11/263,737 patent/US20070015697A1/en not_active Abandoned
-
2006
- 2006-07-18 DE DE602006006575T patent/DE602006006575D1/de active Active
- 2006-07-18 JP JP2008522862A patent/JP2009501797A/ja active Pending
- 2006-07-18 EP EP09004643A patent/EP2074994A1/de not_active Withdrawn
- 2006-07-18 DK DK06787603T patent/DK1904056T3/da active
- 2006-07-18 AT AT06787603T patent/ATE429914T1/de active
- 2006-07-18 ES ES06787603T patent/ES2326550T3/es active Active
- 2006-07-18 BR BRPI0612859-9A patent/BRPI0612859A2/pt not_active IP Right Cessation
-
2007
- 2007-10-31 US US11/931,938 patent/US20080102101A1/en not_active Abandoned
-
2009
- 2009-01-02 US US12/348,096 patent/US20090143282A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE602006006575D1 (de) | 2009-06-10 |
EP2074994A1 (de) | 2009-07-01 |
US20090143282A1 (en) | 2009-06-04 |
BRPI0612859A2 (pt) | 2010-11-30 |
US20070014760A1 (en) | 2007-01-18 |
DK1904056T3 (da) | 2009-08-10 |
JP2009501797A (ja) | 2009-01-22 |
US20070015697A1 (en) | 2007-01-18 |
ES2326550T3 (es) | 2009-10-14 |
US20080102101A1 (en) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE429914T1 (de) | Verwendung von makroliden zur wiederherstellung der kornealempfindungen | |
Seitz et al. | Inverse mushroom-shaped nonmechanical penetrating keratoplasty using a femtosecond laser | |
NO2013016I1 (no) | Okriplasmin | |
WO2008140052A1 (ja) | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 | |
WO2007070866A3 (en) | Control of intraocular pressure using alk5 modulation agents | |
EA201300272A1 (ru) | Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
ATE535257T1 (de) | Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin | |
WO2007011880A3 (en) | Enhanced ocular neuroprotection/neurostimulation | |
WO2009137085A3 (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
TW200505402A (en) | Ophthalmic drug delivery device | |
DK1973541T3 (da) | Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer | |
CL2007002386A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica. | |
NZ602479A (en) | Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion | |
UY28202A1 (es) | Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares. | |
CY1111384T1 (el) | Διαμορφωση των επιπεδων εκφρασης toy trpv | |
Balparda et al. | Corneal collagen cross-linking. A review of its clinical applications | |
AU2001267864A1 (en) | Remedial agent for optic nerve disease and the like | |
JPWO2019181967A1 (ja) | 非侵襲的角膜又は強膜強化装置 | |
WO2010020878A3 (es) | Anillos cónicos para la succión de la cornea durante la realización de queratectomias de tipo lasik | |
Imamura et al. | Corneal bed perforation by laser ablation during laser in situ keratomileusis | |
林浤裕 | Results of Wavefront Guided EpiLASIK Long Term Results of Wavefront Guided LASIK in High Myopia | |
Salam et al. | Effect of myopic laser in situ keratomileusis on corneal sensitivity | |
WO2009031575A1 (ja) | リチウム塩を有効成分として含有する後眼部疾患の治療又は予防剤 | |
UA86346C2 (ru) | Способ лечения открытоугольной глаукомы | |
Master | Study: Laser therapy more effective at 2 years than triamcinolone for DME patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1904056 Country of ref document: EP |